Extend Biosciences Advances EXT608 to a Phase 1 Clinical Trial with a SBIR Phase IIB Award

NIDDK continues to fund Extend Biosciences’ long-acting PTH for hypoparathyroidism with a Phase IIB grant for the conduct of a Phase 1 trial in healthy volunteers.